eXoZymes Inc. $(EXOZ)$, a leader in AI-engineered enzymes, has announced a significant breakthrough in biomanufacturing using their cell-free exozyme platform. The company, together with its spinout NCTx, successfully transitioned from proof-of-concept to lab scale validation, achieving gram-scale production of the NCT compound in only five months. This achievement addresses a longstanding bottleneck in sourcing NCT, which naturally occurs in trace amounts. The biomanufacturing process demonstrated an impressive 96% reaction yield. Currently, eXoZymes is conducting a comprehensive assessment of the purity profile of the initial batch and plans to release the exact data upon completion of their internal report. The results have already been achieved and highlight the potential of the 'powered by eXoZymes' platform to produce valuable chemicals efficiently.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1051512) on July 22, 2025, and is solely responsible for the information contained therein.
